PE20231442A1 - Proteinas actrii y sus usos - Google Patents
Proteinas actrii y sus usosInfo
- Publication number
- PE20231442A1 PE20231442A1 PE2022002515A PE2022002515A PE20231442A1 PE 20231442 A1 PE20231442 A1 PE 20231442A1 PE 2022002515 A PE2022002515 A PE 2022002515A PE 2022002515 A PE2022002515 A PE 2022002515A PE 20231442 A1 PE20231442 A1 PE 20231442A1
- Authority
- PE
- Peru
- Prior art keywords
- polypeptide
- seq
- acid sequence
- amino acid
- amino acids
- Prior art date
Links
- 102100021886 Activin receptor type-2A Human genes 0.000 title 1
- 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a un kit que comprende un polipeptido liofilizado y un dispositivo de inyeccion, en el que el polipeptido es un polipeptido ActRII que comprende una secuencia de aminoacidos que sea al menos 70 %, 75 %, 80 %, 85 %, 86 %, 87 %, 88 %, o hasta 100 % identica a una secuencia de aminoacidos que comienza en cualquiera de los aminoacidos 21, 22, 23, 24, 25, o hasta 30 de SEQ ID NO: 1 y termina en uno cualquiera de los aminoacidos 110, 111, 112, 113, o hasta 135 de SEQ ID NO: 1. En donde dicho polipeptido es una proteina de fusion que comprende ademas un dominio de fusion Fc de una inmunoglobulina. Tambien se refiere a su uso para tratar, prevenir o reducir la tasa de progresion y/o la gravedad de la hipertension pulmonar poscapilar (PcPH).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016942P | 2020-04-28 | 2020-04-28 | |
| US202163159253P | 2021-03-10 | 2021-03-10 | |
| PCT/US2021/029492 WO2021222322A1 (en) | 2020-04-28 | 2021-04-27 | Actrii proteins and use in treating post-capillary pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231442A1 true PE20231442A1 (es) | 2023-09-14 |
Family
ID=78332188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002515A PE20231442A1 (es) | 2020-04-28 | 2021-04-27 | Proteinas actrii y sus usos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230174620A1 (es) |
| EP (1) | EP4142769A4 (es) |
| JP (1) | JP2023529278A (es) |
| KR (1) | KR20230017193A (es) |
| CN (1) | CN115867306A (es) |
| AU (1) | AU2021263760A1 (es) |
| BR (1) | BR112022021861A2 (es) |
| CA (1) | CA3176701A1 (es) |
| CL (1) | CL2022002953A1 (es) |
| CO (1) | CO2022016210A2 (es) |
| EC (1) | ECSP22089513A (es) |
| IL (1) | IL297627A (es) |
| MX (1) | MX2022013592A (es) |
| PE (1) | PE20231442A1 (es) |
| WO (1) | WO2021222322A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4190805A3 (en) * | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| PT3496739T (pt) * | 2016-07-15 | 2021-06-21 | Acceleron Pharma Inc | Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar |
| AU2018214629A1 (en) * | 2017-02-06 | 2019-08-22 | Acceleron Pharma Inc. | Compositions and methods for treating heart failure |
| US10982000B2 (en) * | 2017-03-24 | 2021-04-20 | Novartis Ag | Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody |
| EP3790572A4 (en) * | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | TYPE IIA ACTIVIN RECEPTOR VARIANTS AND METHODS OF USE THEREOF |
-
2021
- 2021-04-27 MX MX2022013592A patent/MX2022013592A/es unknown
- 2021-04-27 BR BR112022021861A patent/BR112022021861A2/pt unknown
- 2021-04-27 CA CA3176701A patent/CA3176701A1/en active Pending
- 2021-04-27 EP EP21797514.3A patent/EP4142769A4/en active Pending
- 2021-04-27 JP JP2022565799A patent/JP2023529278A/ja active Pending
- 2021-04-27 KR KR1020227041262A patent/KR20230017193A/ko active Search and Examination
- 2021-04-27 AU AU2021263760A patent/AU2021263760A1/en active Pending
- 2021-04-27 US US17/921,810 patent/US20230174620A1/en active Pending
- 2021-04-27 WO PCT/US2021/029492 patent/WO2021222322A1/en active Application Filing
- 2021-04-27 IL IL297627A patent/IL297627A/en unknown
- 2021-04-27 CN CN202180044420.8A patent/CN115867306A/zh active Pending
- 2021-04-27 PE PE2022002515A patent/PE20231442A1/es unknown
-
2022
- 2022-10-25 CL CL2022002953A patent/CL2022002953A1/es unknown
- 2022-11-11 CO CONC2022/0016210A patent/CO2022016210A2/es unknown
- 2022-11-21 EC ECSENADI202289513A patent/ECSP22089513A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115867306A (zh) | 2023-03-28 |
| WO2021222322A1 (en) | 2021-11-04 |
| JP2023529278A (ja) | 2023-07-10 |
| EP4142769A1 (en) | 2023-03-08 |
| US20230174620A1 (en) | 2023-06-08 |
| AU2021263760A1 (en) | 2022-11-24 |
| CL2022002953A1 (es) | 2023-04-21 |
| MX2022013592A (es) | 2023-01-18 |
| ECSP22089513A (es) | 2023-03-31 |
| IL297627A (en) | 2022-12-01 |
| EP4142769A4 (en) | 2024-05-15 |
| KR20230017193A (ko) | 2023-02-03 |
| BR112022021861A2 (pt) | 2023-01-24 |
| CA3176701A1 (en) | 2021-11-04 |
| CO2022016210A2 (es) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119235A1 (es) | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO | |
| PE20091488A1 (es) | Proteinas de una sola cadena y union multivalente con funcion efectora | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| NO20063026L (no) | Antistoffer | |
| AR071874A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| DE112006000677A5 (de) | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| PE20090311A1 (es) | Proteinas de fusion natriureticas | |
| ECSP064643A (es) | Proteinas de fusion de glp-1 | |
| AR119080A1 (es) | Proteínas multiespecíficas | |
| AR005651A1 (es) | Proteina de fusion, vector de expresion para dicha proteina, cepa de escherichia coli que expresa dicha proteina, uso de dicha proteina, composicion de vacuna que comprende la proteina, metodo para la purificacion de la proteina y anticuerpo monoclonal empleado en el metodo | |
| DE60036552D1 (de) | Fc-fusionsproteine zur erhöhung der immunogenität von protein- und peptid-antigenen | |
| AR109680A1 (es) | Proteínas recombinantes y sus usos | |
| PE20130593A1 (es) | DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA | |
| BR112018003594A2 (pt) | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados | |
| AR123158A1 (es) | Proteínas de fusión del ligando para flt3 y métodos de uso | |
| CY1114526T1 (el) | Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων | |
| PE20231442A1 (es) | Proteinas actrii y sus usos | |
| DE60335726D1 (de) | Chromoprotein und fluoroproteine | |
| ATE307826T1 (de) | Oligomere von konformationsbeschränkten, nicht- peptidischen di- oder tripeptid-mimetika, und ihre verwendung zur synthese von künstlichen polypeptiden und proteinen | |
| AR080774A1 (es) | Peptido senal, y su utilizacion para la produccion de proteinas recombinantes | |
| AR009647A1 (es) | Un polinucleotido de hebras simples o dobles aislado, un vector que lo comprende, uso de un vector para transformar una celula huesped, un polipeptidoaislado y purificado y un procedimiento recombinante para la expresion de un polipeptido que es codificado por dicho polinucleotido. | |
| ES2557938T3 (es) | Antagonistas de resistina y su uso | |
| ATE466876T1 (de) | Immunogene konstrukte | |
| AR125263A1 (es) | Nuevo conjugado de análogo de il-2 inmunoestimulante y su método de preparación |